Human papillomavirus (HPV) infection has become one of the most important health problems faced by women all over the world. A large number of studies have shown that women's cervical, vaginal and perianal precancerous lesions, related cancers, condyloma acuminatum and other sexually transmitted diseases (STD) are closely related to HPV infection. Among them, the persistent infection of high-risk human papillomavirus (HR-HPV) is closely related to the occurrence of invasive cervical cancer. Previous studies have shown that there are significant differences in the effects of multiple HPV infection and persistent infection of different types (such as type-16, -18, -39 and -52) on different levels of cervical lesions, and there is a certain correlation between HPV load in the process of persistent infection and the degree of cervical lesions. In addition, other studies have shown that HPV-16 viral load has certain clinical significance in predicting Cin2 / CIN3 high-grade cervical lesions, and HPV viral load level is significantly different in cervical low-grade squamous intraepithelial lesion (LSIL) and cervical high-grade squamous intraepithelial lesion (HSIL). The above biological changes such as HPV infection type, quantity and proportion can promote the occurrence and development of cervical precancerous lesions and related cancers to varying degrees. It can be seen that the study of the relationship between HPV viral load and cervical lesions is of great significance for clinical disease development prediction and cervical cancer screening.
Age range
20 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Cervical histopathology testing at baseline
Timeframe: Baseline
Cervical histopathology testing at 6-month follow-up
Timeframe: 6-month follow-up
Cervical histopathology testing at 12-month follow-up
Timeframe: 12-month follow-up
Cervical histopathology testing at 24-month follow-up
Timeframe: 24-month follow-up
Human Papillomavirus (HPV) viral load test at baseline
Timeframe: Baseline
Human Papillomavirus (HPV) viral load test at 6-month follow-up
Timeframe: 6-month follow-up
Human Papillomavirus (HPV) viral load test at 12-month follow-up
Timeframe: 12-month follow-up
Human Papillomavirus (HPV) viral load test at 24-month follow-up
Timeframe: 24-month follow-up
Cervical cytology testing at baseline
Timeframe: Baseline
Cervical cytology testing at 6-month follow-up
Timeframe: 6-month follow-up
Cervical cytology testing at 12-month follow-up
Timeframe: 12-month follow-up
Cervical cytology testing at 24-month follow-up
Timeframe: 24-month follow-up
16SrRNA sequencing of the vaginal secretions at baseline
Timeframe: Baseline
16SrRNA sequencing the vaginal secretions at 6-month follow-up
Timeframe: 6-month follow-up
16SrRNA sequencing of the vaginal secretions at 12-month follow-up
Timeframe: 12-month follow-up
16SrRNA sequencing of the vaginal secretions at 24-month follow-up
Timeframe: 24-month follow-up